The overall goal of this revised grant application is to investigate the function and mechanism of action of vif in HIV- l infection of peripheral blood lymphocytes (PBL). vif has been considered an accessory (nonessential) gene for HIV-l infection in T cell lines, but its function is essential for stable HIV-l replication in PBL. Through the analysis of paired vif-positive and negative isogeneic HIV-l clones we have shown that the vif-negative virus replication is distinguished by inefficient viral DNA synthesis which results in impaired viral production in T cell lines and abortive infection in PBL. We hypothesize that in PBL vif is absolutely required for the proper assembly and/or maturation of progeny virus and that vif-negative virions produced in PBL are non-infectious due to defects in virus entry, internalization, or reverse transcription. To test this hypothesis we propose: l) To examine the physical and biochemical properties of vif -negative HIV- l produced in PBL; 2) To characterize the biologic dysfunctions of PBL-derived vif-negative HIV- related to defective viral DNA synthesis and abortive infection of PBL; 3) To investigate the mechanism of action of vif in HIV- l infection in PBL by studies of: a) subcellular localization of vif; b) role of vif in virion assembly; c) vif association with viral proteins; 4) To determine the functional domains of vif by mutagenesis; and 5) To analyze the structure and function of vif genes present in HIV- l infected persons. The proposed studies will employ paired vif-positive and vif-negative isogeneic HIV- l clones, vaccinia virus-based gag-pol and vif expression vectors, and retroviral vif expression vectors, to achieve HIV- l infection and efficient expression of specific viral products in normal PBL. vif-negative HIV- l will be produced in PBL through efficient single- cycle infection with a SupT l derived vif mutant HIV-l. vif-negative virions from PBL will be characterized by biophysical and biochemical methods, and tested for their binding, virus-cell fusion (by membrane fluorescence dequenching), viral DNA synthesis and integration (by PCR). Viral protein composition will be studied by radioimmunoprecipitation; vif-viral protein interaction by cross-linking and Western blotting; functional domains of vif by site directed mutagenesis and complementation assays. vif gene sequences will be amplified directly from PBL of HIV- positive patients by PCR, cloned, sequenced, and functionally evaluated. These studies will provide the fundamental knowledge regrading the control of HIV-l infection in PBL and will contribute the design of antiviral therapy to block HIV- l infection through vif.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI035466-01A2
Application #
2071140
Study Section
AIDS and Related Research Study Section 2 (ARRB)
Project Start
1994-09-01
Project End
1998-05-31
Budget Start
1994-09-01
Budget End
1995-05-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
St. Luke's-Roosevelt Institute for Health Sciences
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10019
Sova, P; Chao, W; Volsky, D J (1997) The redox state of cysteines in human immunodeficiency virus type 1 Vif in infected cells and in virions. Biochem Biophys Res Commun 240:257-60
Kotler, M; Simm, M; Zhao, Y S et al. (1997) Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol 71:5774-81
Simm, M; Pekarskaya, O; Volsky, D J (1996) Synthesis of full-length viral DNA in CD4-positive membrane vesicles exposed to HIV-1. A model for studies of early stages of the hiv-1 life cycle. J Biol Chem 271:28266-70
Chowdhury, I H; Chao, W; Potash, M J et al. (1996) vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol 70:5336-45
Simm, M; Chao, W; Pekarskaya, O et al. (1996) Genetic variability and function of the long terminal repeat from syncytium-inducing and non-syncytium-inducing human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 12:801-9
Simm, M; Shahabuddin, M; Chao, W et al. (1995) Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol 69:4582-6
Sova, P; van Ranst, M; Gupta, P et al. (1995) Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol 69:2557-64
Volsky, D J; Potash, M J; Simm, M et al. (1995) The human immunodeficiency virus type 1 vif gene: the road from an accessory to an essential role in human immunodeficiency virus type 1 replication. Curr Top Microbiol Immunol 193:157-68